HomeCompareCI vs BSX

CI vs BSX: Dividend Comparison 2026

CI yields 2.36% · BSX yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CI wins by $133.46M in total portfolio value
10 years
CI
CI
● Live price
2.36%
Share price
$258.08
Annual div
$6.09
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$133.48M
Annual income
$123,432,595.24
Full CI calculator →
BSX
BSX
● Live price
3.18%
Share price
$62.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full BSX calculator →

Portfolio growth — CI vs BSX

📍 CI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCIBSX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CI + BSX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CI pays
BSX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CI
Annual income on $10K today (after 15% tax)
$200.58/yr
After 10yr DRIP, annual income (after tax)
$104,917,705.95/yr
BSX
Annual income on $10K today (after 15% tax)
$270.14/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
At 15% tax rate, CI beats the other by $104,917,705.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CI + BSX for your $10,000?

CI: 50%BSX: 50%
100% BSX50/50100% CI
Portfolio after 10yr
$66.75M
Annual income
$61,716,297.78/yr
Blended yield
92.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BSX right now

CI
Analyst Ratings
1
Strong
31
Buy
7
Hold
Consensus: Buy
Price Target
$325.83
+26.3% upside vs current
Range: $300.00 — $375.00
Altman Z
2.7
Piotroski
7/9
BSX
Analyst Ratings
2
Strong
38
Buy
3
Hold
Consensus: Buy
Price Target
$108.35
+72.2% upside vs current
Range: $94.00 — $130.00
Altman Z
3.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CI buys
9
BSX buys
6
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Gilbert Cisneros🏢 House$BSX▼ Sell$1,001 - $15,0002025-12-24
Julie Johnson🏢 House$CI▼ Sell$1,001 - $15,0002025-12-18
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-11-18
Julie Johnson🏢 House$CI▼ Sell$1,001 - $15,0002025-11-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCIBSX
Forward yield2.36%3.18%
Annual dividend / share$6.09$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%-50%
Portfolio after 10y$133.48M$20.2K
Annual income after 10y$123,432,595.24$0.32
Total dividends collected$132.70M$321.00
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusBuyBuy
Analyst price target$325.83$108.35

Year-by-year: CI vs BSX ($10,000, DRIP)

YearCI PortfolioCI Income/yrBSX PortfolioBSX Income/yrGap
1← crossover$11,172$471.95$10,859$158.91+$313.00CI
2$12,940$985.53$11,700$80.63+$1.2KCI
3$15,979$2,133.55$12,559$40.60+$3.4KCI
4$22,022$4,924.66$13,459$20.36+$8.6KCI
5$36,250$12,686.29$14,411$10.20+$21.8KCI
6$77,820$39,032.84$15,425$5.10+$62.4KCI
7$239,893$156,625.47$16,507$2.55+$223.4KCI
8$1,159,158$902,472.79$17,664$1.28+$1.14MCI
9$9,391,197$8,150,897.78$18,901$0.64+$9.37MCI
10$133,481,176$123,432,595.24$20,225$0.32+$133.46MCI

CI vs BSX: Complete Analysis 2026

CIHealthcare

The Cigna Group provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care delivery and management, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans to on and off the public exchanges; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

Full CI Calculator →

BSXHealthcare

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Full BSX Calculator →
📬

Get this CI vs BSX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CI vs SCHDCI vs JEPICI vs OCI vs KOCI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.